EDIT-401's preclinical data is highly encouraging with ~90% reductions across multiple atherogenic lipoproteins, positioning it as a potential best-in-class therapy for hyperlipidemia. The positive FDA feedback and clear regulatory path to human trials by mid-2026 are key catalysts. Traders should monitor for CTN submission and early proof-of-concept data by year-end 2026, which could drive significant upside given the large addressable market.
Price Chart
Executive Summary
Editas Medicine presented preclinical data for EDIT-401 at the EAS Congress, showing a single dose achieved ~90% mean reductions in LDL-C, Lp(a), and ApoB in non-human primates. The company also received positive pre-IND feedback from the FDA and plans to submit a CTN in Australia by mid-2026, with early human proof-of-concept data expected by end of 2026. For an early-stage biotech with a $270M market cap, this is a significant pipeline catalyst that supports the stock's bullish narrative.
Key Facts
- Single dose of EDIT-401 achieved ~90% mean reduction in LDL-C, Lp(a), and ApoB in NHPs
- Reductions were rapid, dose-dependent, and highly correlated, supporting unified LDLR upregulation mechanism
- Positive pre-IND feedback received from FDA on nonclinical package, CMC plans, and study design
- Company plans to submit CTN in Australia by mid-2026 for first-in-human trial in HeFH patients
- Early in vivo human proof-of-concept data for EDIT-401 expected by end of 2026
- EDIT-401 was well-tolerated in ongoing GLP toxicology study with no adverse observations at 1.5 mg/kg
Financial Impact
No financial data provided; pipeline catalyst for a pre-revenue biotech with $270M market cap
Risk Factors
- Preclinical results may not translate to human efficacy or safety
- Regulatory approval for clinical trials is not guaranteed despite positive pre-IND feedback
- Company is pre-revenue with limited cash runway; potential need for future financing
- Competition from existing PCSK9 inhibitors and other gene editing approaches
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300882 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.84 | awaiting T+20 | — | $2.40 (−15.49%) |
Sep 9, 2026 6w ago | EFFECT | $2.77 $2.75 | ▼ −0.72% | ▼ −2.92% | $2.40 (−13.36%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.44 $3.30 | ▲ +35.25% | ▲ +33.35% | $2.40 (−1.64%) |
May 26, 2026 21w ago | 424B5 | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | 8-K | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | 8-K | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
May 26, 2026 22w ago | 424B5 | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 22w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 22w ago | Press Release | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers